Disease · MONDO_0007256
Comparisons in its trials180
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 180
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sunitinib vs Sorafenib: serious adverse events | 240 of 526 | 204 of 542 | 1,068 | NCT00699374 | Trial comparisons |
| Lenvatinib vs Sorafenib: deaths from any cause | 415 of 478 | 402 of 476 | 954 | NCT01761266 | Trial comparisons |
| Lenvatinib vs Sorafenib: serious adverse events | 209 of 476 | 149 of 475 | 951 | NCT01761266 | Trial comparisons |
| Orantinib vs Placebo: deaths from any cause | 33 of 444 | 24 of 444 | 888 | NCT01465464 | Trial comparisons |
| Orantinib vs Placebo: serious adverse events | 200 of 444 | 134 of 444 | 888 | NCT01465464 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo: deaths from any cause | 314 of 395 | 352 of 399 | 794 | NCT03713593 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo: Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 51 of 395 | 41 of 395 | 790 | NCT03713593 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo: Number of Participants Who Experienced an Hepatic Event of Clinical Interest (HECI) | 71 of 395 | 77 of 395 | 790 | NCT03713593 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo: Number of Participants Who Experienced an Immune-related Adverse Event (irAE) of Clinical Interest | 210 of 395 | 184 of 395 | 790 | NCT03713593 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo: Number of Participants Who Experienced an Serious Adverse Event (SAE) | 185 of 395 | 159 of 395 | 790 | NCT03713593 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo: Number of Participants Who Experienced an Adverse Event (AE) | 394 of 395 | 392 of 395 | 790 | NCT03713593 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo: serious adverse events | 185 of 395 | 159 of 395 | 790 | NCT03713593 | Trial comparisons |
| Nivolumab 240 mg vs Sorafenib 400 mg: deaths from any cause | 321 of 371 | 335 of 372 | 743 | NCT02576509 | Trial comparisons |
| Nivolumab 240 mg vs Sorafenib 400 mg: serious adverse events | 216 of 367 | 216 of 363 | 730 | NCT02576509 | Trial comparisons |
| Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) vs Sorafenib (Nexavar, BAY 43-9006) + Placebo: Tumor Response | 24 of 362 | 14 of 358 | 720 | NCT00901901 | Trial comparisons |
| Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) vs Sorafenib (Nexavar, BAY 43-9006) + Placebo: Disease Control | 159 of 362 | 188 of 358 | 720 | NCT00901901 | Trial comparisons |
| Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva) vs Sorafenib (Nexavar, BAY43-9006) + Placebo: serious adverse events | 214 of 362 | 198 of 355 | 717 | NCT00901901 | Trial comparisons |
| Cabozantinib (XL184) vs Placebo: Objective Response Rate (ORR) | 18 of 470 | 1 of 237 | 707 | NCT01908426 | Trial comparisons |
| Cabozantinib (XL184) vs Placebo: deaths from any cause | 314 of 467 | 167 of 237 | 704 | NCT01908426 | Trial comparisons |
| Cabozantinib (XL184) vs Placebo: serious adverse events | 232 of 467 | 87 of 237 | 704 | NCT01908426 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007256/comparisons